BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2271934)

  • 1. Chronic testosterone propionate treatment decreases the concentration of [3H]quipazine binding at 5-HT3 receptors in the amygdala of the castrated male rat.
    Mendelson SD; McEwen BS
    Brain Res; 1990 Oct; 528(2):339-43. PubMed ID: 2271934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoradiography of [3H]quipazine in rodent brain.
    Perry DC
    Eur J Pharmacol; 1990 Oct; 187(1):75-85. PubMed ID: 2272355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of 5-HT3 receptor binding assay: enhancement of specific [3H]quipazine binding with Triton X-100-treated membranes from rat cortex.
    Une T; Furukawa K; Komiya M
    Jpn J Pharmacol; 1991 Oct; 57(2):197-203. PubMed ID: 1812298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
    Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
    Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
    Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
    Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of [3H]quipazine binding to 5-hydroxytryptamine3 receptors in rat brain membranes.
    Milburn CM; Peroutka SJ
    J Neurochem; 1989 Jun; 52(6):1787-92. PubMed ID: 2566650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands.
    Barnes JM; Barnes NM; Costall B; Jagger SM; Naylor RJ; Robertson DW; Roe SY
    Br J Pharmacol; 1992 Feb; 105(2):500-4. PubMed ID: 1559139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of trichloroethanol with murine recombinant 5-HT3 receptors.
    Downie DL; Hope AG; Belelli D; Lambert JJ; Peters JA; Bentley KR; Steward LJ; Chen CY; Barnes NM
    Br J Pharmacol; 1995 Apr; 114(8):1641-51. PubMed ID: 7541281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography.
    Kilpatrick GJ; Jones BJ; Tyers MB
    Neurosci Lett; 1988 Nov; 94(1-2):156-60. PubMed ID: 3241663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone modulates oxytocin binding in the hypothalamus of castrated male rats.
    Johnson AE; Coirini H; McEwen BS; Insel TR
    Neuroendocrinology; 1989 Aug; 50(2):199-203. PubMed ID: 2550840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species variations in 5-HT3 recognition sites labeled by 3H-quipazine in the central nervous system.
    Peroutka SJ
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Nov; 338(5):472-5. PubMed ID: 3244388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.
    Peroutka SJ; Hamik A
    Eur J Pharmacol; 1988 Mar; 148(2):297-9. PubMed ID: 3378579
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-HT transporter sites and 5-HT1A and 5-HT3 receptors in Fawn-Hooded rats: a quantitative autoradiography study.
    Chen F; Lawrence AJ
    Alcohol Clin Exp Res; 2000 Jul; 24(7):1093-102. PubMed ID: 10924015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of testosterone-induced dominance by the serotonergic agonist quipazine.
    Bonson KR; Winter JC
    Pharmacol Biochem Behav; 1992 Aug; 42(4):809-13. PubMed ID: 1513863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminative-stimulus effects of quipazine and l-5-hydroxytryptophan in relation to serotonin binding sites in the pigeon.
    Walker EA; Yamamoto T; Hollingsworth PJ; Smith CB; Woods JH
    J Pharmacol Exp Ther; 1991 Nov; 259(2):772-82. PubMed ID: 1941625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.
    Glennon RA; Ismaiel AE; McCarthy BG; Peroutka SJ
    Eur J Pharmacol; 1989 Sep; 168(3):387-92. PubMed ID: 2583244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive behavior inhibition by serotonin and quipazine injected into the amygdala in the rat.
    Puciłowski O; Płaźnik A; Kostowski W
    Behav Neural Biol; 1985 Jan; 43(1):58-68. PubMed ID: 4039562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of 5-HT3 receptors in the rat brain using [3H]LY278584.
    Gehlert DR; Gackenheimer SL; Wong DT; Robertson DW
    Brain Res; 1991 Jul; 553(1):149-54. PubMed ID: 1933271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
    Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
    J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.